News Capsule - National

Jubilant's arm signs research pact with AstraZeneca

Our News Bureau - Mumbai

Jubilant Organosys's subsidiary, Jubilant Biosys has signed a research collaboration agreement with AstraZeneca for focused attention on delivering novel drug candidates into the AstraZeneca's pre-clinical pipeline. AstraZeneca will own the compounds developed under the collaboration with worldwide development and commercialisation rights. Jubilant will be eligible to receive research funding spanning an initial five-year period.

Under the shared risk-reward collaboration, which will initially focus on the neuroscience area, Jubilant aims to deliver a steady stream of discovery programmes to AstraZeneca. In addition, AstraZeneca will also pay Jubilant success-based development milestones, as well as royalties based on successful global commercialisation of any of the compounds.

Shyam S Bhartia, Chairman and Managing Director and Hari S Bhartia, Co-Chairman and Managing Director, Jubilant Organosys said, "We are very pleased to partner with AstraZeneca. This collaboration will leverage the innovative capabilities of AstraZeneca and Jubilant Biosys in providing a robust global drug discovery model. Through this partnership, Jubilant is confident of contributing to AstraZeneca's preclinical portfolio and anticipates significant rewards from successful downstream milestones."

Jan Lundberg, Executive Vice-President, Global Discovery, AstraZeneca commented, "This collaboration complements our internal capabilities and increases the capacity of our pre-clinical programmes. It is a concrete example of the innovative approaches we are taking to deliver a sustainable discovery pipeline with a lean and agile organisation. Ultimately, this will provide us with more shots on goal as we look to sustain a competitive portfolio and provide meaningful medicines to patients."